Merrimack Pharmaceuticals

Merrimack CEO, CFO bow out, months after last clinical drug fizzles
Merrimack CEO, CFO bow out, months after last clinical drug fizzles
Endpoints
Merrimack Pharmaceuticals
MM-310
Flag link:
Merrimack to Lay Off Remaining Execs and Staff, Sell Assets
Merrimack to Lay Off Remaining Execs and Staff, Sell Assets
BioSpace
Merrimack Pharmaceuticals
layoffs
Flag link:
Merrimack zero for 3 as it dumps cancer drug over safety fears, axes staffers (again)
Merrimack zero for 3 as it dumps cancer drug over safety fears, axes staffers (again)
Fierce Biotech
Merrimack Pharmaceuticals
adverse events
layoffs
MM-310
Flag link:
Merrimack cuts 60% of jobs, narrows R&D focus
Merrimack cuts 60% of jobs, narrows R&D focus
Biopharma Dive
Merrimack Pharmaceuticals
layoffs
R&D
MM-121
Flag link:
Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop
Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop
Endpoints
Merrimack Pharmaceuticals
MM-121
non-small cell lung cancer
Flag link:
Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat
Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat
Endpoints
pancreatic cancer
MM-141
Merrimack Pharmaceuticals
Flag link:
These 3 Biotechs Have Been Crushed
These 3 Biotechs Have Been Crushed
Motley Fool
Xbiotech
Merrimack Pharmaceuticals
NewLink Genetics
Flag link:
Monday’s 4 Biggest Biopharma Movers
Monday’s 4 Biggest Biopharma Movers
Yahoo/24-7 Wall St
Ariad Pharma
Arrowhead
Alcobra
Merrimack Pharmaceuticals
Flag link:
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal
Yahoo/Reuters
Ipsen
France
Merrimack Pharmaceuticals
pancreatic cancer
Onivyde
Flag link:
​Sales of Merrimack’s new pancreatic cancer drug top $11M in Q1
​Sales of Merrimack’s new pancreatic cancer drug top $11M in Q1
Bizjournals.com
Merrimack Pharmaceuticals
Onivyde
pancreatic cancer
Flag link:
3 Scorned Biotechs Destined to Rebound
3 Scorned Biotechs Destined to Rebound
TheStreet.com
Merrimack Pharmaceuticals
Relypsa
Amgen
AbbVie
Dynavax
Flag link:
FDA clears Merrimack's pancreatic cancer drug with warning
FDA clears Merrimack's pancreatic cancer drug with warning
Yahoo/Reuters
FDA
Merrimack Pharmaceuticals
pancreatic cancer
warnings
Onivyde
Flag link:
​With pending drug approval, Merrimack Pharma set to be area's next commercial biotech
​With pending drug approval, Merrimack Pharma set to be area's next commercial biotech
Bizjournals.com
Merrimack Pharmaceuticals
MM-398
FDA
Flag link:
U.S. FDA Grants Priority Review for MM-398 New Drug Application
U.S. FDA Grants Priority Review for MM-398 New Drug Application
Yahoo
FDA
MM-398
Merrimack Pharmaceuticals
metastatic pancreatic cancer
Flag link:
Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Yahoo
Merrimack Pharmaceuticals
Baxter International
MM-398
metastatic pancreatic cancer
Flag link:
Merrimack pancreatic cancer product candidate fast tracked
Merrimack pancreatic cancer product candidate fast tracked
Seeking Alpha
pancreatic cancer
Merrimack Pharmaceuticals
FDA
fast track
Flag link:
Merrimack Does Well to License Marginal Cancer Drug to Baxter
Merrimack Does Well to License Marginal Cancer Drug to Baxter
TheStreet.com
Merrimack Pharmaceuticals
MM-398
pancreatic cancer
Baxter International
Flag link:
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
Yahoo/Benzinga
FDA
drug approvals
Acadia
Alexion
InterMune
Merrimack Pharmaceuticals
Soliris
pimavanserin
MM-398
Esbriet
Flag link:
The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
24/7 Wall St
Alexion
InterMune
FDA
Acadia
Kythera
Intercept Pharmaceuticals
Merrimack Pharmaceuticals
Relypsa
MM-398
patiromer
Esbriet
ATX-101
Soliris
Flint
pimavanserin
Flag link:
Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights
Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights
Yahoo/Zacks.com
Sanofi
Merrimack Pharmaceuticals
MM-121
Flag link:

Pages